Latest news with #BioMarin
Yahoo
16-07-2025
- Business
- Yahoo
Looking for a Growth Stock? 3 Reasons Why BioMarin (BMRN) is a Solid Choice
Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's attention and deliver solid returns. But finding a growth stock that can live up to its true potential can be a tough task. In addition to volatility, these stocks carry above-average risk by their very nature. Also, one could end up losing from a stock whose growth story is actually over or nearing its end. However, it's pretty easy to find cutting-edge growth stocks with the help of the Zacks Growth Style Score (part of the Zacks Style Scores system), which looks beyond the traditional growth attributes to analyze a company's real growth prospects. BioMarin Pharmaceutical (BMRN) is on the list of such stocks currently recommended by our proprietary system. In addition to a favorable Growth Score, it carries a top Zacks Rank. Studies have shown that stocks with the best growth features consistently outperform the market. And for stocks that have a combination of a Growth Score of A or B and a Zacks Rank #1 (Strong Buy) or 2 (Buy), returns are even better. Here are three of the most important factors that make the stock of this rare disease biopharmaceutical a great growth pick right now. Earnings Growth Earnings growth is arguably the most important factor, as stocks exhibiting exceptionally surging profit levels tend to attract the attention of most investors. For growth investors, double-digit earnings growth is highly preferable, as it is often perceived as an indication of strong prospects (and stock price gains) for the company under consideration. While the historical EPS growth rate for BioMarin is 40.9%, investors should actually focus on the projected growth. The company's EPS is expected to grow 23% this year, crushing the industry average, which calls for EPS growth of 19.7%. Cash Flow Growth Cash is the lifeblood of any business, but higher-than-average cash flow growth is more beneficial and important for growth-oriented companies than for mature companies. That's because, high cash accumulation enables these companies to undertake new projects without raising expensive outside funds. Right now, year-over-year cash flow growth for BioMarin is 83.6%, which is higher than many of its peers. In fact, the rate compares to the industry average of -4.7%. While investors should actually consider the current cash flow growth, it's worth taking a look at the historical rate too for putting the current reading into proper perspective. The company's annualized cash flow growth rate has been 40.1% over the past 3-5 years versus the industry average of 4.1%. Promising Earnings Estimate Revisions Beyond the metrics outlined above, investors should consider the trend in earnings estimate revisions. A positive trend is a plus here. Empirical research shows that there is a strong correlation between trends in earnings estimate revisions and near-term stock price movements. The current-year earnings estimates for BioMarin have been revising upward. The Zacks Consensus Estimate for the current year has surged 0.1% over the past month. Bottom Line BioMarin has not only earned a Growth Score of B based on a number of factors, including the ones discussed above, but it also carries a Zacks Rank #1 because of the positive earnings estimate revisions. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. This combination indicates that BioMarin is a potential outperformer and a solid choice for growth investors. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report BioMarin Pharmaceutical Inc. (BMRN) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
12-07-2025
- Business
- Yahoo
Morgan Stanley Sees Rebound Potential in BioMarin (BMRN), Highlights Underappreciated Voxzogo Upside
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the 11 best debt-free stocks to invest in right now. On July 2, Morgan Stanley analyst Sean Laaman initiated coverage on BioMarin with a Buy rating and a $97 price target, citing a favorable outlook despite ongoing competitive concerns. Laaman's optimism centers on Voxzogo, BioMarin's therapy for achondroplasia, a rare disorder affecting bone growth. While Ascendis Pharma's TransCon CNP could pose competition due to its longer half-life, Laaman notes that it still faces key challenges, including ongoing patent litigation. Importantly, he believes investors may be underestimating Voxzogo's broader potential, particularly in other indications such as hypochondroplasia. A close up photograph of a vial of a new biotechnological drug candidate in development. The analyst also pointed to the CANOPY clinical program, which is evaluating Voxzogo in conditions linked to SHOX gene mutations, as a promising path for further label expansion. In Laaman's view, this pipeline optionality is not fully reflected in BioMarin's current valuation. Trading near a 10-year low, the stock appears to already account for most of the perceived risks. Given the strength of Voxzogo's current performance, expansion potential, and an underappreciated pipeline, Laaman sees a compelling upside case for BioMarin shares from current levels. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is a biotechnology company that develops and commercializes therapies for rare diseases and medical conditions worldwide. While we acknowledge the potential of BMRN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Harvard University Stock Portfolio: Top 10 Stock Picks and . Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
28-06-2025
- Business
- Yahoo
BioMarin's ROCTAVIAN Shows Sustained Efficacy, Safety Over 5 Years for Severe Hemophilia A
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the most undervalued US stocks according to analysts. On June 24, BioMarin Pharmaceutical Inc. presented new 5-year data from its Phase 3 GENEr8-1 trial at the 33rd Congress of the International Society on Thrombosis and Haemostasis/ISTH in Washington, D.C., which took place from June 21 to 25. The data reinforced the long-term efficacy and safety of ROCTAVIAN (valoctocogene roxaparvovec-rvox) as a gene therapy for severe hemophilia A. The GENEr8-1 trial is the longest and largest hemophilia gene therapy study to date, and demonstrated sustained Factor VIII (FVIII) expression and durable bleed control 5 years after a single treatment with ROCTAVIAN. A pharmaceutical plant manufacturing a proprietary synthetic oral form of a C-type natriuretic peptide. FVIII activity remained consistent with previously reported results. Importantly, no new safety signals were observed over the 5-year study period. Across all 134 participants who received ROCTAVIAN in the study, there were no cases of FVIII inhibitors or thromboembolic events, and no treatment-related malignancies were observed. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is a biotechnology company that develops and commercializes therapies for life-threatening rare diseases and medical conditions internationally. While we acknowledge the potential of BMRN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
23-06-2025
- Business
- Yahoo
Barclays Initiates BioMarin Pharmaceutical Inc. (BMRN) with a Buy Rating
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds. Gena Wang of Barclays kept BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) at a Buy rating with a price target of $86.00 in a report published on June 10. A pharmaceutical plant manufacturing a proprietary synthetic oral form of a C-type natriuretic peptide. According to BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)'s most recent earnings report, the firm made $745.15 million in revenue and $185.69 million in net profit for the quarter that ended on March 31. The company's sales were $648.83 million, and its net profit was $88.66 million last year. It is challenging to avoid past comparisons with Genzyme (bought by Sanofi) as BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) builds a portfolio of genetic-disease therapies. Despite having several authorized treatments, the firm spent years in the red due to commercialization and R&D costs, but analysts are optimistic about the long-term, profitable potential of its present portfolio. It is in a strong position because of its extensive internal pipeline and capacity to add expansion through strategic acquisitions. While we acknowledge the potential of BMRN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None.
Yahoo
16-06-2025
- Business
- Yahoo
Jim Cramer on BioMarin: 'I Don't Think It Works Now'
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the 16 stocks Jim Cramer recently discussed. When a caller asked about the company during the lightning round, Cramer remarked: 'You know what, BioMarin, I am getting tired of the orphan drug model. I just… [don't] think that it's working. I think it worked for some time. I don't think it works now.' A pharmaceutical plant manufacturing a proprietary synthetic oral form of a C-type natriuretic peptide. BioMarin (NASDAQ:BMRN) is a biotechnology company focused on turning genetic research into treatments that significantly improve patients' lives, supported by a history of innovation and a growing pipeline of therapies. It is worth noting that in 2023, when Cramer was asked about the company during a lightning round, he commented, 'I would hold onto that one.' Since the comment was aired back in January 2023, BMRN stock has gone down more than 49%. While we acknowledge the potential of BMRN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
